Skip to main content
. 2018 Apr 13;8(4):236. doi: 10.3390/nano8040236

Figure 9.

Figure 9

Viability of cancer and normal cells after being treated with tHBcAg VLNPs conjugated with doxorubicin and folic acid at equal DOX concentrations. Viability of cancer (a) HeLa; (b) HT29 cells; and normal (c) 3T3; (d) CCD-112 cells. tHBcAg VLNPs conjugated with folic acid (FA) and doxorubicin (DOX) (FA-tHBcAg-DOX) were more efficient in inhibiting the growth of cancer HeLa and HT29 cells than other formulations. By contrast, conjugation of DOX to the FA-conjugated tHBcAg VLNPs led to a decrease in cytotoxicity on normal 3T3 and CCD-112 cells, resulting in protection of the normal cells against DOX. Data represent means ± SDs of triplicate determinations. The small graphs on the right show that tHBcAg VLNPs (tHBcAg) are not toxic to the tested cancer and normal cells.